Table 4.

Univariable and Multivariable Cox-PH Regression Analysis of the Time from CRPC to Death.

	Univariable		Multivariable
	HR (95% CI)	p-value	HR (95% CI)	p-value
Age at Diagnosis (years)		0.19		0.19
Group A <55	0.96 (0.61 - 1.52)	0.85	0.73 (0.44 - 1.20)	0.21
Group B 55 -64	0.82 (0.61 - 1.11)	0.19	0.76 (0.55 - 1.05)	0.10
Group C 65 - 74	Reference		Reference
Group D≥75	1.30 (0.86 - 1.98)	0.21	1.07 (0.68 - 1.69)	0.76
Presence of Visceral Disease (Yes vs No)	1.95 (1.41-2.70)	<0.0001	2.01 (1.40 - 2.88)	<0.0001
Absolute PSA Nadir on ADT (≥4 vs <4 ng/ml)	1.99 (1.47 - 2.69)	<0.0001	1.90 (1.37 - 2.64)	<0.0001
Time to Nadir on ADT (<6 vs ≥6 months)	2.27 (1.71 - 3.01)	<.0001	1.64 (1.19 - 2.26)	0.003
Duration of Hormone Sensitivity (≥12 vs <12 mo)	0.61 (0.42 - 0.88)	0.009	0.66 (0.46 - 0.94)	0.02
PSA at Diagnosis		0.05		0.01
0 - <10	Reference		Reference
10 - <20	0.85 (0.55 - 1.32)	0.46	0.81 (0.49 - 1.33)	0.40
20 - <100	0.67 (0.45 - 0.99)	0.67	0.64 (0.43 - 0.94)	0.02
≥100	1.12 (0.75 - 1.69)	0.58	0.48 (0.29 - 0.79)	0.004
Gleason at Diagnosis		0.09		0.63
<=6	Reference		Reference
7	0.92 (0.54 - 1.57)	0.76	0.88 (0.51 - 1.52)	0.65
8-10	1.30 (0.79 - 2.15)	0.30	1.02 (0.59 - 1.73)	0.96
CCI at time of diagnosis		0.50		0.22
0	Reference		Reference
1-2	0.93 (0.70 - 1.24)	0.64	0.80 (0.59 - 1.10)	0.17
3+	1.20 (0.79 - 1.82)	0.39	0.81 (0.51 - 1.26)	0.35
Stage at Diagnosis		<0.0001		0.06
1-2	Reference		Reference
3	0.75 (0.51 - 1.11)	0.15	1.01 (0.68 - 1.50)	0.20
4	1.53 (1.09 - 2.17)	0.02	2.21 (1.42 - 3.44)	0.59
Time from Dx to CRPC (per 1 month increase)	0.994(0.991-0.998)	0.002	0.996 (0.992 - 1.001)	0.11
Peripheral Anti-androgen Withdrawal Response
No	Reference		Reference
Yes	0.89 (0.65 - 1.23)	0.47	0.85 (0.58 - 1.23)	0.39